Showing results (41-50 of 128) with videos related to
Sort By:
Pageof 13
Blood Advances|September 24, 2021
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphomaChristopher J Forlenza, Nitya Gulati, Audrey Mauguen, et al.Blood Advances|January 26, 2021
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responsesVanessa A Fabrizio, M Irene Rodriguez-Sanchez, Audrey Mauguen, et al.The Oncologist|March 25, 2010
Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancerCyril Touboul, Catherine Uzan, Audrey Mauguen, et al.JAMA Oncology|December 22, 2022
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical TrialIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2021
Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapiesSimone Krebs, Audrey Mauguen, Onur Yildirim, et al.Cancers|December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk NeuroblastomaFiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.Transplantation and Cellular Therapy|June 3, 2021
Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation OutcomesGabriela Llaurador, Eileen Nicoletti, Susan E Prockop, et al.Journal of Pediatric Hematology/Oncology|February 3, 2025
Treatment of T-cell Leukemia/Lymphoma in Children and Young Adults With the Memorial Sloan Kettering Cancer Center New York IIB ProtocolPeter G Steinherz, Audrey Mauguen, Stephanie Suser, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2025
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete RemissionBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease ProgressionIrene Y Cheung, Nai-Kong V Cheung, Shakeel Modak, et al.Pageof 13